The most common AEs in the RT plus sorafenib group were decreased WBC count (n = 33, 60.0%), decreased platelet count (n = 23, 41.8%), anemia (n = 28, 50.9%), increased aspartate aminotransferase (n = 32, 58.2%), increased alanine aminotransferase (n = 27, 49.1%), increased bilirubin (n = 24, 43.6%), fatigue (n = 20, 36.4%), nausea (n = 22, 40%), vomiting (n = 10, 18.2%), and diarrhea (n = 10, 18.2%). This evidence concerns the gene GPT and anemia.